WATERTOWN, Mass., May 21, 2025 - Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company, has announced a definitive merger agreement with Sanofi $(SNY)$. Under the terms of the agreement, Sanofi will acquire all outstanding common shares of Vigil for $8.00 per share in cash, amounting to an equity value of approximately $470 million. Additionally, Vigil's shareholders will receive a non-tradeable contingent value right $(CVR)$ entitling them to an additional $2.00 per share in cash, contingent on the first commercial sale of VG-3927. The acquisition is anticipated to bolster Sanofi's neurology focus, particularly in advancing the TREM2 agonist program, including VG-3927, a Phase 2-ready candidate for Alzheimer's treatment. The companies expect the transaction to close in the third quarter of 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。